(Reuters) - LONDON, April 3 - GlaxoSmithKline Plc has taken a step forward in developing a successor to its top-seller Advair, as rivals snap at its dominant position in respiratory medicine.
Industry analysts said positive mid-stage trials with a new inhaled long-acting beta agonist , announced late on Monday by U.S. partner Theravance Inc , showed Glaxo's replacement for Advair was taking shape.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment